"But the most important distinction of A2-73 and the entire platform of sigma-1 activation is that we've now been able to learn, very recently, that sigma-1 activation goes even further upstream into the nucleus...and its been able to show that it prevents cellular stress before and after RNA translation.
So in regards to that, chromatin remodeling is restored, as well as post-translation proteins - which are toxic - are prevented, by preventing toxic RNA to be expressed into toxic proteins. So only healthy proteins are expressed by expressing healthy RNA".
Feels good to be invested in the leading sigma-1 biotech company that has numerous patents on its drugs.
Only 40 more weeks before the AD clinical trial is completed. (This will be HUGE!!!)
12 - 16 weeks before we get results from the AVATAR Rett trial that could be pivotal...or is 4 - 12 weeks? (I guess we'll find out when it's announced. LOL)
Market Data 
Markets 
AI
